Latham & Watkins Advises 4D Molecular Therapeutics on US$100 Million Offering of Common Stock and Pre-Funded Warrants

4D Molecular Therapeutics (Nasdaq: FDMT), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, has announced the pricing of an underwritten offering of 8,385,809 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,128,949 shares of common stock. The shares of common stock are being sold at a price of US$10.51 per share and the pre-funded warrants are being sold at a price of US$10.5099 per pre-funded warrant, which represents the per share price for the common stock less the US$0.0001 per share exercise price for each pre-funded warrant. The gross proceeds from the offering are expected to be approximately US$100 million before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares and pre-funded warrants in the offering are to be sold by 4D Molecular Therapeutics. The offering is expected to close on November 7, 2025, subject to satisfaction of customary closing conditions.

Latham & Watkins LLP represents 4D Molecular Therapeutics in the transaction with a corporate team led by Bay Area partners Mark Roeder and John Williams, with associates Raul Gonzalez-Casarrubias, Lexi Zintel, and Keran Huang. Advice was also provided on regulatory matters by Washington, D.C. partner Elizabeth Richards, Bay Area partner Betty Pang, and Washington, D.C. counsel Chad Jennings, with associate Evan Miller; on data privacy and cybersecurity matters by Bay Area partner Heather Deixler, with associate Sarah Zahedi; on tax matters by Bay Area partner Grace Lee, with associate Dennis Poehland; on benefits and compensation matters by Bay Area partner Maj Vaseghi; and on intellectual property matters by San Diego/Bay Area partner Christopher Hazuka and San Diego counsel Robert Yeh, with associate Kristina Funahashi.